Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether Nanoxel®M is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesica...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Samyang Biopharmaceuticals Corporation
NCT06663137 · Non Muscle Invasive Bladder Cancer
NCT06287541 · Non Muscle Invasive Bladder Cancer
NCT04452591 · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
NCT06111235 · Non Muscle Invasive Bladder Cancer, Urologic Cancer, and more
NCT06181266 · NMIBC, High Risk NMIBC, and more
Seoul National University Hospital
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions